Drug Profile
Research programme: myostatin inhibitors - MYOS Corporation
Latest Information Update: 16 Mar 2022
Price :
$50
*
At a glance
- Originator Cloud Pharmaceuticals; MYOS Corporation
- Class Small molecules
- Mechanism of Action Furin modulators; Janus kinase 3 inhibitors; Myostatin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Atopic dermatitis
- No development reported Cachexia; Sarcopenia
Most Recent Events
- 16 Mar 2022 Preclinical trials in Atopic dermatitis in USA (unspecified route) (Cloud Pharmaceuticals pipeline, March 2022)
- 28 Aug 2018 No recent reports of development identified for research development in Cachexia in USA
- 28 Aug 2018 No recent reports of development identified for research development in Sarcopenia in USA